{"prompt": "['Protocol', 'ALXN1210-MG-306 Amendment 2', '9.4.6.6.', 'Analysis of Exploratory Biomarkers', '67', '9.5.', 'Interim Analyses', '67', '9.6.', 'Data Monitoring Committee', '67', '10.', 'SUPPORTING DOCUMENTATION AND OPERATIONAL', 'CONSIDERATIONS', '68', '10.1.', 'Appendix 1: Regulatory, Ethical, and Study Oversight Considerations', '68', '10.1.1.', 'Regulatory and Ethical Considerations', '68', '10.1.2.', 'Informed Consent Process', '68', '10.1.3.', 'Data Protection', '69', '10.1.4.', 'Dissemination of Clinical Study Data', '69', '10.1.5.', 'Data Quality Assurance', '69', '10.1.6.', 'Source Documents', '70', '10.1.7.', 'Study and Site Closure', '70', '10.1.8.', 'Publication Policy', '71', '10.2.', 'Appendix 2: Clinical Laboratory Tests', '72', '10.3.', 'Appendix 3: Adverse Events: Definitions and Procedures for Recording,', 'Evaluating, Follow-up, and Reporting', '73', '10.3.1.', 'Adverse Event', '73', '10.3.2.', 'Serious Adverse Event', '74', '10.3.3.', 'Suspected Unexpected Serious Adverse Reactions', '74', '10.3.4.', 'Recording and Follow-Up of Adverse Event and/or Serious Adverse Event', '75', '10.3.5.', 'Reporting of Serious Adverse Events', '76', '10.4.', 'Appendix 4: Contraceptive Guidance and Collection of Pregnancy', 'Information', '78', '10.4.1.', 'Contraception Guidance', '78', '10.4.2.', 'Pregnancy Testing', '78', '10.4.3.', 'Collection and Reporting of Pregnancy Information', '79', '10.5.', 'Appendix 5: Management of Potential Infusion-Associated Adverse Events', 'During Study Drug Administration', '80', '10.6.', 'Appendix 6: Myasthenia Gravis Activities of Daily Living Profile', '82', '10.7.', 'Appendix 7: Quantitative Myasthenia Gravis Score for Disease Severity', '83', '10.8.', 'Appendix 8: Myasthenia Gravis Composite Scale', '84', '10.9.', 'Appendix 9: Euro Quality of Life Questionnaire', '85', '10.10.', 'Appendix 10: Myasthenia Gravis Quality-of-Life 15r Scale', '88', 'Page 12 of 109', 'Alexion Confidential']['Protocol', 'ALXN1210-MG-306 Amendment 2', '10.11.', 'Appendix 11: Neurology Quality of Life Fatigue', '89', '10.12.', 'Appendix 12: Myasthenia Gravis Foundation of America Clinical', 'Classification', '91', '10.13.', 'Appendix 13: Myasthenia Gravis Foundation of America Post-Interventional', 'Status', '92', '10.14.', 'Appendix 14: Columbia-Suicide Severity Rating Scale - Baseline/Screening', '(Version 1/14/09)', '93', '10.15.', 'Appendix 15: Columbia-Suicide Severity Rating Scale - Since Last Visit', '(Version 1/14/09)', '96', '10.16.', 'Appendix 16: Statistical Considerations', '99', '10.16.1.', 'Additional Details on Sample Size Determination', '99', '10.16.2.', 'Additional Details on Sensitivity Analysis for Primary Endpoint', '99', '10.16.2.1. Placebo-based Sensitivity Analysis', '99', '10.16.2.2. Tipping Point Sensitivity Analysis', '99', '10.17.', 'Appendix 17: Abbreviations', '101', '10.18.', 'Appendix 18: Protocol Amendment History', '104', '11.', 'REFERENCES', '107', 'LIST OF TABLES', 'Table 1:', 'Schedule of Activities: Screening Through End of the Randomized-', 'Controlled Period', '20', 'Table 2:', 'Schedule of Activities: Extension Period', '23', 'Table 3:', 'Myasthenia Gravis Assessments and Responsibilities', '34', 'Table 4:', 'Ravulizumab Weight-Based Dosing', '35', 'Table 5:', 'Study Drug Administered', '40', 'Table 6:', 'Reference Chart for Weight-Based Dosing', '41', 'Table 7:', 'Supplemental Dose When Plasmapheresis/Plasma Exchange is Administered', 'as Rescue Therapy on Nonscheduled Dosing Visits', '47', 'Table 8:', 'Supplemental Dose When Intravenous Immunoglobulin is Administered as', 'Rescue Therapy on Nonscheduled Dosing Visits', '48', 'Table 9:', 'Study ALXN1210-MG-306: Analysis Sets', '63', 'Table 10: Protocol-Required Safety Laboratory Assessments', '72', 'Table 11: List of Abbreviations and Definitions of Terms', '101', 'Page 13 of 109', 'Alexion Confidential']\n\n###\n\n", "completion": "END"}